12 results about "Heart transplants" patented technology

A method for performing a robotic-assisted orthotopic heart transplant includes forming a working port subareolarly by a mini-thoracotomy at a working intercostal space, forming additional ports for robotic arms, and arranging robotic arms through the ports. A first robotic arm with first forceps extends through a second port lateral to a mid-clavicular line, while second and third robotic arms containing an imaging device and second forceps operate through the working port. A fourth robotic arm with scissors or needle holder extends through a third port proximal to an anterior axillary line. The method includes cannulating for cardiopulmonary bypass, opening the pericardium, cross-clamping the aorta, removing the native heart, and performing sequential anastomoses of the donor heart including the left atrium, pulmonary artery, aorta, inferior vena cava, and superior vena cava.

The application discloses an application of niclosamide in treating organ transplant rejection. The application discloses that niclosamide can specifically interfere with the TMEM16F-CLIC1 interaction, thereby inhibiting the uptake of donor EVs by DCs, prolonging the survival time of a heart transplant by interfering with the 'costume change' of recipient DCs and inhibiting T cell activation, and indicating a new use of niclosamide in transplant immunoregulation.

The invention provides a heart transplantation nutrition prognosis analysis system for a patient with dilated cardiomyopathy, three factors including prealbumin (PA), total bile acid (TBA) and NRS2002 score are incorporated into the analysis system, a corresponding algorithm is provided, and based on the algorithm, the optimal cutoff value of an undesirable outcome is predicted to be 0.121, the sensitivity is 72.9%, the specificity is 92.9%, and the area under a ROC curve (AUC) is 0.885 (95% CI: 0.802-0.967); when the absolute error of a calibration curve is 0.049, the HL goodness of fit test is equal to 6.134 (P is equal to 0.632 gt, 0.05), the net income threshold probability of DCA is 0.04-0.94, and the threshold probability of CIC is greater than 0.50, the prediction is highly consistent with the actual outcome. Meanwhile, the AUC value of the algorithm is obviously larger than that of other existing prediction methods, the algorithm can serve as a reliable tool for evaluating the postoperative adverse outcome risk of the patient in clinical practice, an important reference basis is provided for optimizing the individualized treatment strategy of the patient to be transplanted and perfecting the organ distribution scheme, and the accuracy and rationality of heart transplantation diagnosis and treatment can be improved.

The invention discloses a connector device for rapid suspension and lossless fixation of aorta in heart transplantation, and relates to the technical field of heart transfer equipment, the connector device comprises a connector main body, the connector main body comprises an aorta connector, and a clamping mechanism is arranged on the circumferential side of the aorta connector; the clamping mechanism comprises a fixing ring, a conical barrel and a plurality of wedge-shaped clamping jaws. Through the arrangement of the aorta connector, the clamping mechanism, the flexible parts and the like, the multiple wedge-shaped clamping jaws clamp and fix the aorta blood vessel wall through axial movement of the conical barrel, the multiple flexible parts make direct contact with the aorta blood vessel wall and wrap the aorta blood vessel wall, damage to the aorta blood vessel wall due to hard contact is avoided, and the aorta blood vessel wall is protected; and compared with a purse-string suture mode, the device has the advantages of stable circumferential clamping force and short operation time.

The invention discloses application of tazeostat in preparation of a medicine for preventing and treating cardiac transplantation chronic rejection, and belongs to the technical field of biological medicine. The medicine reduces the trimethylation level of histone H3 around a B cell p21 gene at a lysine 27 site through epigenetic regulation, relieves epigenetic inhibition on the p21 gene to highly express p21 molecules, influences differentiation of the B cell to a hair growth center B cell and plasma cells, and further relieves antibody-mediated rejection reaction, so that the survival time of a graft is remarkably prolonged, and the survival rate of the graft is improved. The function of the transplanted heart is improved.

The invention relates to the technical field of medical image processing and artificial intelligence analysis, in particular to a mechanical perfusion heart coronary artery recognition and flow velocity estimation method based on laser speckle imaging, and is suitable for donor heart function evaluation and organ quality screening before heart transplantation. Comprising the following steps: continuously imaging the surface of an isolated heart in a mechanical perfusion state to acquire a dynamic speckle image sequence, inputting the dynamic speckle image sequence into a wavelet enhancement nnU-Net model to generate a coronary artery segmentation mask, and applying the coronary artery segmentation mask to the dynamic speckle image sequence to extract image data only containing a coronary artery region, and then generating a blood flow index map, analyzing the periodic change of the blood flow index in the coronary artery region to construct a blood flow velocity change curve, and estimating the hemodynamic parameters of the coronary artery. According to the application, automatic coronary artery identification and quantitative estimation of the blood flow velocity can be carried out on the mechanically perfused isolated heart, so that rapid and accurate non-invasive evaluation on the coronary artery system of the donor heart before heart transplantation is realized.

The present invention provides, among other things, methods of using IL-2 fusion proteins, comprising an IL-2 variant and an Pc region, to treat and / or prevent heart transplant rejections. Methods of treating heart disease or a symptom thereof, conditioning a subject for heart transplant, modulating immunosuppression, and selectively increasing regulatory T cells are also disclosed.

The invention features methods for the treatment of a cardiovascular disease using a polypeptide containing an extracellular ActRII variant, such as an ActRIIA variant, ActRIIB variant, or ActRII chimera. The polypeptide may include an extracellular ActRII variant fused to an Fc domain monomer. Treatment of a cardiovascular disease with a polypeptide described herein may reduce fibrosis, reduce inflammation, reduce cardiac remodeling, improve cardiac function, improve ventricular function, or slow or inhibit disease progression, which may reduce or delay the need for coronary revascularization, heart valve repair or replacement, implantation of a cardioverter-defibrillator, cardiac resynchronization therapy, a ventricular assist device, or a heart transplant.

The invention provides application of bacteroides simplex derived outer membrane vesicles in acute rejection of heart transplantation, and belongs to the technical field of biological medicines. According to the application of the bacteroides simplex-derived outer membrane vesicles in preparation of the medicine for preventing or treating heart transplantation rejection reaction, the immune level of the transplantation position after organ transplantation is adjusted by introducing the intestinal microorganism-derived extracellular vesicles, and the problem that the toxic and side effects are remarkable after an immunosuppressive agent is used for a long time is solved; and a new thought is provided for development of immunosuppressants.

A perivascular valve device includes a valve body and define an integral tubular blood outlet passageway sidestem extending perpendicularly from said valve body, the outlet passageway being continuous with a lumen of the blood vessel, wherein the perivascular valve is selectively positional, such that the perivascular valve with sidestem can be positioned at any anatomically available level and rotational angle along the blood vessel. The outlet passageway can have a driven polymeric tongue having an upturned front end configured as a blood outflow diversion chute which is extendable a controllable distance into the lumen of the blood vessel so as to draw off a controllable volume of blood between zero and one hundred percent into said passageway for discharge through the outlet passageway sidestem. The valve body comprises a stretchable material comprising expandable furrows to allow radial expansion of the perivascular valve so as to accommodate growth in pediatric patients.

The invention provides application of parabacteroides dielsii-derived outer membrane vesicles in acute rejection of heart transplantation, and belongs to the technical field of biological medicines. The invention provides the application of the outer membrane vesicles derived from the parabacteroides dieldrii in preparation of the medicine for relieving acute rejection of heart transplantation, and the outer membrane vesicles derived from the parabacteroides dieldrii have good biocompatibility and immune negative regulation capability, can effectively relieve acute rejection of organ transplantation immune, and can be used for preparing the medicine for relieving acute rejection of heart transplantation. The toxic and side effects caused by long-term use of the immunosuppressor are reduced, a new thought and scheme are provided for the development of the novel immunosuppressor, and the application prospect is wide.

The invention discloses an application of a GSDMD molecular inhibitor NU6300 in preparation of a medicine for treating heart transplantation rejection. The GSDMD molecular inhibitor NU6300 is applied to a constructed heart transplantation model, and after treatment of the GSDMD molecular inhibitor NU6300, it is observed that the survival time of heart grafts of an experimental group and a control group is prolonged, the GSDMD-mediated pyroptosis level is reduced, and the infiltration degree of inflammatory cytokines in the grafts is weakened. Therefore, the invention can provide a new therapeutic drug for treating patients after organ transplantation, and can be applied to organ transplantation treatment.